The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis

키워드

참고문헌 (72)

1. Iacobuzio-Donahue CA, "DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer", J Clin Oncol, 27, pp.1806~1813 (2009)[DOI]
2. Moertel CG, "Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: The Gastrointestinal Tumor Study Group", Cancer, 48, pp.1705~1710 (1981)[DOI]
3. Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)[DOI]
4. Chauffert B, "Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD", SFRO study, 2008, pp.19, 1592~1599
5. Loehrer PJ Sr, "Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial", J Clin Oncol, 29, pp.4105~4112 (2011)[DOI]
6. Sultana A, "Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation", combined modality therapy, 2007, pp.96, 1183~1190
7. Huguet F, "Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies", J Clin Oncol, 25, pp.326~331 (2007)[DOI]
8. Krishnan S, "Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy", Cancer, 110, pp.47~55 (2007)[DOI]
9. Hammel P, "Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial", JAMA, 315, pp.1844~1853 (2016)[DOI]
10. Abrams RA, "Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704: a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas", Int J Radiat Oncol Biol Phys, 82, pp.809~816 (2012)[DOI]
11. Moher D, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement", PLoS Med, 6, pp.e1000097~ (2009)[DOI]
12. Schwarzer G, "meta: an R package for meta-analysis", R News, 7, pp.40~45 (2007)
13. Freeman MF, "Transformations related to the angular and the square root", Ann Math Stat, 21, pp.607~611 (1950)[DOI]
14. Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)[DOI]
15. Lau J, "Quantitative synthesis in systematic reviews", Ann Intern Med, 127, pp.820~826 (1997)[DOI]
16. Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)[DOI]
17. Sterne JA, "Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis", BMJ, 323, pp.101~105 (2001)[DOI]
18. Hazel JJ, "Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial", J Can Assoc Radiol, 32, pp.164~165 (1981)
19. Klaassen DJ, "Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil: an Eastern Cooperative Oncology Group study", J Clin Oncol, 3, pp.373~378 (1985)[DOI]
20. "Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group", J Natl Cancer Inst, 80, pp.751~755 (1988)[DOI]
21. Todd KE, "Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole", J Gastrointest Surg, 2, pp.159~166 (1998)[DOI]
22. Conroy T, "Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer: a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study", J Clin Oncol, 23, pp.1228~1236 (2005)[DOI]
23. Isacoff WH, "Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700", J Clin Oncol, 25, pp.1665~1669 (2007)[DOI]
24. Chauffert B, "Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: definitive results of the 2000-01 FFCD", SFRO study, 2008, pp.19, 1592~1599
25. Ishii H, "Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506", Jpn J Clin Oncol, 40, pp.573~579 (2010)[DOI]
26. Loehrer PJ Sr, "Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial", J Clin Oncol, 29, pp.4105~4112 (2011)[DOI]
27. Sahora K, "NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer", World J Surg, 35, pp.1580~1589 (2011)[DOI]
28. Sahora K, "NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer", Surgery, 149, pp.311~320 (2011)[DOI]
29. Lee JL, "Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma", Surgery, 152, pp.851~862 (2012)[DOI]
30. Nakai Y, "A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study", Br J Cancer, 106, pp.1934~1939 (2012)[DOI]
31. Ozaka M, "Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)", Cancer Chemother Pharmacol, 69, pp.1197~1204 (2012)[DOI]
32. Heinemann V, "Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer", Br J Cancer, 108, pp.766~770 (2013)[DOI]
33. Ueno M, "Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: results of the Japan Clinical Oncology Group study (JCOG0805)", J Clin Oncol, 30(15 Suppl), pp.4031~ (2012)
34. Stein S, "Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC)", J Clin Oncol, 33(15 Suppl), pp.e15274~ (2015)
35. Hammel P, "Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial", JAMA, 315, pp.1844~1853 (2016)[DOI]
36. Wagener DJ, "Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer", Cancer Chemother Pharmacol, 25, pp.131~134 (1989)[DOI]
37. Wagener DJ, "Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study", Eur J Cancer, 32A, pp.1310~1313 (1996)
38. Epelbaum R, "Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer", J Surg Oncol, 81, pp.138~143 (2002)[DOI]
39. Al-Sukhun S, "Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study", Am J Clin Oncol, 26, pp.543~549 (2003)[DOI]
40. Mishra G, "Phase II trial of induction gemcitabine", CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer, 2005, pp.28, 345~350
41. Kurt E, "Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer", Tumori, 92, pp.481~486 (2006)
42. Ko AH, "A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer", Int J Radiat Oncol Biol Phys, 68, pp.809~816 (2007)[DOI]
43. Goldstein D, "Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer", Br J Cancer, 97, pp.464~471 (2007)[DOI]
44. Moureau-Zabotto L, "Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study", J Clin Oncol, 26, pp.1080~1085 (2008)[DOI]
45. Marti JL, "Phase I", II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer, 2008, pp.15, 3521~3531
46. Landry J, "Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma", J Surg Oncol, 101, pp.587~592 (2010)[DOI]
47. Nakachi K, "A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer", Cancer Chemother Pharmacol, 66, pp.527~534 (2010)[DOI]
48. Ch'ang HJ, "Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil", leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study, 2011, pp.81, e749~e757
49. Crane CH, "Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression", J Clin Oncol, 29, pp.3037~3043 (2011)[DOI]
50. Milandri C, "GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer", Hepatogastroenterology, 58, pp.599~603 (2011)
51. Goldstein D, "The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer", Br J Cancer, 106, pp.61~69 (2012)[DOI]
52. Kim JS, "Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer", Cancer Chemother Pharmacol, 70, pp.381~389 (2012)[DOI]
53. Leone F, "Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience", Cancer, 119, pp.277~284 (2013)[DOI]
54. Mukherjee S, "SCALOP: results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC)", J Clin Oncol, 31(4 Suppl), pp.LBA146~ (2013)[DOI]
55. Youl M, "Induction gemcitabine plus concurrent gemcitabine and radiotherapy for locally advanced unresectable or resected pancreatic cancer", Clin Oncol (R Coll Radiol), 26, pp.203~209 (2014)[DOI]
56. Esnaola NF, "Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer", Int J Radiat Oncol Biol Phys, 88, pp.837~844 (2014)[DOI]
57. Ke QH, "S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer", World J Gastroenterol, 20, pp.13987~13992 (2014)[DOI]
58. Herman JM, "Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma", Cancer, 121, pp.1128~1137 (2015)[DOI]
59. Faisal F, "Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer", Am J Clin Oncol, 39, pp.18~26 (2016)[DOI]
60. Simkens LH, "Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group", Lancet, 385, pp.1843~1852 (2015)[DOI]
61. Weinberg BA, "Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study", Gastrointest Cancer Res, 7, pp.91~97 (2014)
62. Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)[DOI]
63. Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)[DOI]
64. Heinemann V, "Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer", J Clin Oncol, 24, pp.3946~3952 (2006)[DOI]
65. Louvet C, "Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial", J Clin Oncol, 23, pp.3509~3516 (2005)[DOI]
66. Mukherjee S, "Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial", Lancet Oncol, 14, pp.317~326 (2013)[DOI]
67. Yang YF, "Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis", Onco Targets Ther, 8, pp.3315~3322 (2015)
68. Vauthey JN, "AHPBA", SSO, Ann Surg Oncol, pp.2009, 16[DOI]
69. Huguet F, "Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations", Int J Radiat Oncol Biol Phys, 83, pp.1355~1364 (2012)[DOI]
70. Trakul N, "Stereotactic body radiotherapy in the treatment of pancreatic cancer", Semin Radiat Oncol, 24, pp.140~147 (2014)[DOI]
71. Whittle MC, "RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma", Cell, 161, pp.1345~1360 (2015)[DOI]
72. Torres-Roca JF, "A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy", Per Med, 9, pp.547~557 (2012)[DOI]

관련 논문AI추천